demonstrate that administering DAT to mice leads to a deceleration in tumor development and amplifies the efficacy of ICI immunotherapy, particularly when combined with anti-CTLA-4 or anti-PD-1 treatments (29). This evidence concerns the gene CTLA4 and neoplasm.